Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: Nonhemodynamic renal protection

Journal of the American Society of Nephrology

Volumn 18, Issue 3, 2007, Pages 750-759

  Yu, Chen ^a,c   Gong, Rujun ^a   Rifai, Abdlla ^b   Tolbert, Evelyn M ^a   Dworkin, Lance D ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CANDESARTAN; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CELL INFILTRATION; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; INFLAMMATION; KIDNEY INJURY; KIDNEY TUBULE; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; TREATMENT OUTCOME;

EID: 33947233679     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006070770     Document Type: Article

References (46)

1. Jackson B, Franze L, Whitty M: Systemic and renovascular hypertension. Tohoku J Exp Med 166: 155-164, 1992
2. Dworkin LD, Feiner HD, Parker M, Tolbert E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 39: 1112-1117, 1991
3. Weir MR: Hypertensive nephropathy: Is a more physiologic approach to blood pressure control an important concern for the preservation of renal function? Am J Med 93: 27S-37S, 1992
4. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000
5. Main IW, Nikolic-Paterson DJ, Atkins RC: T cells and macrophages and their role in renal injury. Semin Nephrol 12: 395-407, 1992
6. Erwig LP, Kluth DC, Rees AJ: Macrophages in renal inflammation. Curr Opin Nephrol Hypertens 10: 341-347, 2001
7. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340: 115-126, 1999
8. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843, 2000
9. Schulz R, Heusch G: Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: Initiation of inflammation. J Hypertens Suppl 24: S123-S129, 2006
10. Brasier AR, Recinos A III, Eledrisi MS: Vascular inflammation and the rennin-angiotensin system. Arterioscler Thromb Vasc Biol 22: 1257-1266, 2002
11. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the rennin-angiotensin system and atherosclerosis. Circulation 100: 1223-1229, 1999
12. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001
13. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mazzano S, Egido J: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82: 12-22, 2002
14. Rodriguez-Iturbe B, Pons H, Quiro Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001
15. Antus B, Exton MS, Rosivall L: Angiotensin II: A regulator of inflammation during renal disease? Int J Immunopathol Pharmacol 14: 25-30, 2001
16. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Investig 104: 1693-1701, 1999
17. Arakawa K, Urata H: Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 36: 638-641, 2000
18. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
19. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shanhinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001
20. Porteri E, Rodella L, Rizzoni D, Rezzani R, Paoardi S, Sleiman I, de Ciuceis C, Gianlucae EM, Castellano BM, Bianchi R, Agabiti-Rosei E: Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Blood Pressure 14: 184-192, 2005
21. Nagai M, Horikoshi K, Izumi T, Seki S, Taniguchi M, Taniguchi I, Mochizuki S: Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 18: 353-362, 2004
22. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB: Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16: 966-976, 2005
23. Fujihara CK, Velho M, Malheiros DM, Zatz R: An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67: 1913-1924, 2005
24. Tolbert EM, Weisstuch J, Feiner DH, Dworkin LD: Onset of glomerular hypertension with aging precedes injury in the spontaneously hypertensive rat. Am J Physiol Renal Physiol 278: F839-F846, 2000
25. Sabbatini M, Pisani A, Uccello F, Fuiano G, Alfieri R, Cesaro A, Andreucci BC: Arginase inhibition slows the progression of renal failure in rats with renal ablation. Am J Physiol Renal Physiol 284: 680-687, 2003
26. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD: Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 15: 2868-2881, 2004
27. Gong R, Rifai A, Tolbert EM, Certracchio JN, Dworkin LD: Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 14: 3047-3060, 2003
28. Sakurai H, Chiba H, Miyoshi H, Dugita T, Toriumi W: IκB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274: 30353-30356, 1999
29. Gahnem F, von Lutterotti N, Camargo MJ, Laragh JH, Sealey JE: Angiotensinogen dependency of blood pressure in two high-renin hypertensive rat models. Am J Hypertens 10: 899-904, 1994
30. Kubo T, Hagiwara Y: Angiotensin II sensitivity of anterior hypothalamic area neurons is enhanced in both spontaneously hypertensive rats and Dahl salt-sensitive rats. Neurosci Lett 397: 297-300, 2006
31. Kubo T, Haigiwara Y: Activities of hypothalamic angiotensin II-sensitive neurons are greatly enhanced even in prehypertensive spontaneously hypertensive rats. Neurosci Lett 397: 74-78, 2006
32. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, Carelli C, Galen FX, Menard J, Corvol P: Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 81: 1899-1910, 1990
33. Kodavanti UP, Schladweiler MC, Ledbetter AD, Watkinson WP, Campen MJ, Winsett DW, Richards JR, Crissman KM, Hatch GH, Costa DL: The spontaneously hypertensive rat as a model of human cardiovascular disease: Evidence of exacerbated cardiopulmonary injury and oxidative stress from inhaled emission particulate matter. Toxicol Appl Pharmacol 164: 250-263, 2000
34. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K: Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46: 843-851, 2003
35. Marks L, Carswell HV, Peters EE, Graham DI, Patterson J, Dominiczak AF, Macrae IM: Characterization of the microglial response to cerebral ischemia in the stroke-prone spontaneously hypertensive rat. Hypertension 38: 116-122, 2001
36. Suzuki Y, Gomez-Guerrero C, Shirato I, Lopez-Franco O, Hernandez-Vargas P, Sanjuan G, Ruiz-Ortega M, Sugaya T, Okumura K, Tomino Y, Ra C, Egido J: Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of rennin-angiotensin system: The role of NF-AT pathway. J Immunol 169: 4136-4146, 2002
37. Suzuki Y, Ruiz-Ortega M, Egido J: Angiotensin II: A double-edged sword in inflammation. J Nephrol 13[Suppl 3]: S101, 2000
38. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blance J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M: Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514-1529, 2004
39. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J: Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: Role of AT(1) and AT(2) receptors. Am J Pathol 158: 1743-1756, 2001
40. Schmeisser A, Soehnlei O, Illmer T, Lorenz HM, Eskafi S, Roerick O, Gabler C, Strasser R, Daniel WG, Garlichs CD: ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-KB activity and AT1 receptor expression. Biochem Biophys Res Commun 325: 532-540, 2004
41. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson Berka JL, Johnston CI, Cooper ME: Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy: Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 155: 429-440, 1999
42. Pelayo JC, Quan AH, Shanley PF: Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physiol 258: F414-F422, 1990
43. Rodriquez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson RJ, Pons HA: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-F201, 2002
44. Cheng HF, Wang JL, Vinson GP, Harris RC: Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule. Am J Physiol Renal Physiol 274: 10-17, 1998
45. Zhou J, Ando H, Macova M, Dou J, Saavedra JM: Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 25: 878-886, 2005
46. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS: Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: A pilot study. Am J Nephrol 24: 340-345, 2004